Publications by authors named "J van Ramshorst"
Article Synopsis
- The study investigates the unique heart failure (HF) characteristics in patients with obesity by analyzing 4210 circulating proteins to identify obesity-specific biomarkers in those with reduced ejection fraction (HFrEF).
- Out of 373 patients monitored over a median of 2.1 years, 26% were classified as obese, and 30% experienced critical heart failure outcomes, showing subtle differences in prognosis between obese and non-obese groups.
- A total of 141 proteins linked to obesity were identified, with 50 of those associated with heart failure outcomes, indicating that these proteins could enhance healthcare strategies for managing obesity-related heart failure and suggest pathways for further research.
Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure: Design and rationale of the BioMEMS study.
Eur J Heart Fail
August 2024
Article Synopsis
- Heart failure (HF) is a widespread issue that requires improved predictive tools for better treatment, particularly focusing on congestion, which leads to hospitalizations.
- The BioMEMS study, part of the MONITOR-HF trial, collects blood samples from participants to analyze the relationship between biomarker patterns and pulmonary artery pressures over time.
- By adopting a dynamic approach to biomarker measurement rather than relying on single baseline values, the study aims to enhance understanding of HF progression and tailor therapies for individual patients.
Article Synopsis
- The TITRATE-HF study investigates the real-world application and barriers to guideline-directed medical therapy (GDMT) for heart failure patients, aligning with the 2021 ESC HF guidelines and 2023 updates.
- Conducted in the Netherlands, the study involved 4,288 patients, highlighting that while 44% of chronic and worsening heart failure patients received quadruple therapy, only 1% achieved target doses for all drug classes.
- The findings indicate that there is significant room for improvement in GDMT usage and dosing, emphasizing the need for enhanced strategies in heart failure management.
Background And Aims: In patients with chronic heart failure (HF), the MONITOR-HF trial demonstrated the efficacy of pulmonary artery (PA)-guided HF therapy over standard of care in improving quality of life and reducing HF hospitalizations and mean PA pressure. This study aimed to evaluate the consistency of these benefits in relation to clinically relevant subgroups.
Methods: The effect of PA-guided HF therapy was evaluated in the MONITOR-HF trial among predefined subgroups based on age, sex, atrial fibrillation, diabetes mellitus, left ventricular ejection fraction, HF aetiology, cardiac resynchronization therapy, and implantable cardioverter defibrillator.
Background: Liver dysfunction contributes to worse clinical outcomes in heart failure (HF) patients. However, studies exploring temporal evolutions of liver function parameters in chronic HF (CHF) pa- tients, and their associations with clinical outcome, are scarce. Detailed temporal patterns of alkaline phosphatase (ALP), gamma glutamyl transpeptidase (GGTP), total bilirubin (TBIL) and albumin (ALB) were investigated, and their relation with clinical outcome, in patients with stable CHF with reduced ejection fraction.
View Article and Find Full Text PDF